期刊文献+

Effect of heme oxygenase-1 on renal function in rats with liver cirrhosis 被引量:8

Effect of heme oxygenase-1 on renal function in rats with liver cirrhosis
下载PDF
导出
摘要 AIM: To investigate the role of heme oxygenase-1 (HO-1) in pathogenesis of experimental hepatorenal syndrome (HRS). METHODS: Rats were divided into liver cirrhotic group, zinc protoporphyrin IX (ZnPP) treatment group, cobalt protoporphyrin (CoPP) treatment group and sham group. Biliary cirrhosis was established by bile duct ligation in the first three groups. Rats in the ZnPP and CoPP treatment groups received intraperitoneal injection of ZnPP and CoPP, respectively, 24 h before sample collection. Expression of HO-1 mRNA in kidney was detected by reverse-transcription polymerase chain reaction, while protein expression was determined by immunohis-tochemical analysis. Hematoxylin and eosin staining was performed to observe liver cirrhosis and renal structure. Renal artery blood flow, mean arterial pressure and portal vein pressure, 24 h total urinary volume, serum and urine sodium concentrations, and creatinine clearance rate (Ccr) were also measured.RESULTS: The HO-1 mRNA and protein expression levels in kidney, 24 h total urinary volume, renal artery blood flow, serum and urine sodium concentration and Ccr were lower in cirrhotic group than in sham group (P < 0.05). However, they were significantly lower in ZnPP treatment group than in cirrhotic group and significantly higher in CoPP treatment group than in cirrhotic group (P < 0.05). CONCLUSION: Low HO-1 expression level in kidney is an important factor for experimental HRS. AIM: To investigate the role of heme oxygenase-1 (HO-1) in pathogenesis of experimental hepatorenal syndrome (HRS). METHODS: Rats were divided into liver cirrhotic group, zinc protoporphyrin IX (ZnPP) treatment group, cobalt protoporphyrin (CoPP) treatment group and sham group. Biliary cirrhosis was established by bile duct ligation in the first three groups. Rats in the ZnPP and CoPP treatment groups received intraperitoneal injection of ZnPP and CoPP, respectively, 24 h before sample collection. Expression of HO-1 mRNA in kidney was detected by reverse-transcription polymerase chain reaction, while protein expression was determined by immunohis-tochemical analysis. Hematoxylin and eosin staining was performed to observe liver cirrhosis and renal structure. Renal artery blood flow, mean arterial pressure and portal vein pressure, 24 h total urinary volume, serum and urine sodium concentrations, and creatinine clearance rate (Ccr) were also measured.RESULTS: The HO-1 mRNA and protein expression levels in kidney, 24 h total urinary volume, renal artery blood flow, serum and urine sodium concentration and Ccr were lower in cirrhotic group than in sham group (P 0.05). However, they were significantly lower in ZnPP treatment group than in cirrhotic group and significantly higher in CoPP treatment group than in cirrhotic group (P 0.05). CONCLUSION: Low HO-1 expression level in kidney is an important factor for experimental HRS.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第3期322-328,共7页 世界胃肠病学杂志(英文版)
基金 Supported by National Natural Science Foundation of China, No. 30970886 Science and Technology Project of Dalian,No. 2008E13SF193
关键词 Heme oxygenase-1 Carbon monoxide Hepatorenal syndrome Zinc protoporphyrin IX Cobalt protoporphyrin Bile duct ligation Biliary cirrhosis 血红素氧化酶-1 肝硬化 肾功能 大鼠 逆转录聚合酶链反应 mRNA表达 锌原卟啉 蛋白表达
  • 相关文献

参考文献34

  • 1Miyazono M, Garat C, Morris KG Jr, Carter EP. Decreased renal heme oxygenase-1 expression contributes to decreased renal function during cirrhosis. Am J Physiol Renal Physiol 2002; 283:F1123-F1131.
  • 2Guevara M, Gin,s P. Hepatorenal syndrome. Dig Dis 2005; 23:47-55.
  • 3Meltzer J, Brentjens TE. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies. Curr Opin Anaesthesiol 2010; 23:139-144.
  • 4Cardenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006; 10: 371-385, ix-x.
  • 5Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37: 233-243.
  • 6Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 2005; 100: 460-467.
  • 7Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1:1066-1079.
  • 8Martin PY, Gin,s P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533-541.
  • 9Turkay C, Yonem O, Arikan O, Baskin E. Nitric oxide and renal functions in fiver cirrhosis. Turk J Gastroenterol 2004; 15:73-76.
  • 10Saracyn M, Wesolowski P, Nowak Z, Patera J, Kozfowski W, Wankowicz Z. [Role of nitric oxide system in pathogenesis of experimental model of hepatorenal syndrome]. Pol Merkur Lekarski 2008; 24:293-297.

同被引文献41

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部